Compare · LSTA vs PGNY
LSTA vs PGNY
Side-by-side comparison of Lisata Therapeutics Inc. (LSTA) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LSTA and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $1.42B, about 49.2x LSTA ($28.9M).
- Over the past year, LSTA is up 31.6% and PGNY is down 20.1% - LSTA leads by 51.6 points.
- PGNY has been more active in the news (5 items in the past 4 weeks vs 2 for LSTA).
- PGNY has more recent analyst coverage (25 ratings vs 0 for LSTA).
- Company
- Lisata Therapeutics Inc.
- Progyny Inc.
- Price
- $3.21-3.89%
- $18.18+2.89%
- Market cap
- $28.9M
- $1.42B
- 1M return
- -36.12%
- +2.42%
- 1Y return
- +31.56%
- -20.05%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 2
- 5
- Recent ratings
- 0
- 25
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest LSTA
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- SEC Form 8-K filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- SEC Form 10-K filed by Lisata Therapeutics Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
Latest PGNY
- Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
- SEC Form 4 filed by Cummings Melissa B
- Progyny Expands Access to Fertility and Women's Health with Industry's First Fully Insured Supplemental Plan
- SEC Form DEFA14A filed by Progyny Inc.
- SEC Form DEF 14A filed by Progyny Inc.
- Progyny Commemorates 10 Years of Redefining Women's Health and Family Building Care
- SEC Form PRE 14A filed by Progyny Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- SEC Form 4 filed by Clapp Geoffrey
- Progyny Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits